Different types of substances come with different risks, these categories can help you understand the type of risks involved.

On this page

    Check your substances

    Use the Sport Integrity App to check your substances

    Download the App

    Sport Integrity App in hand

    TGA Registered medicines (AUST-R)

    The products are the lowest risk due to their high level of regulation. AUST-R products have been fully assessed by the Therapeutic Goods Administration (TGA) for safety, quality and efficacy before they are sold. There is no doping risk to athletes if they choose to use an Australian registered medication, as long as there is no prohibited substance declared on the label.

    Batch-tested products

    As this testing is targeted at WADA prohibited substances, these are the next lowest risk group. We advise athletes that batch-testing, while not a 100% guarantee, lowers doping risk.

    TGA Listed medicines (AUST-L)

    As these products have less regulation than registered medicines and are not specifically tested for WADA Prohibited Substances, they have a higher risk of doping than both registered medicines and batch-tested products.

    For listed medicines, we educate athletes that due to the lower level of regulation there may be an inadvertent doping risk associated with these products. There have been examples of vitamin products obtained overseas which have been contaminated with WADA prohibited substances. These were potentially lower quality manufacturers, but this does highlight the risk with such products.

    Our advice regarding listed medications (such as vitamins and minerals) is that athletes should choose a batch-tested listed medication over a non batch-tested one.

    Non batch-tested, non AUST-L products

    These products have the highest anti-doping risk and should be avoided by athletes. The Sport Integrity App includes hundreds of batch-tested products that athletes should choose from instead.

    Supplement risk analysis factsheet

    Download the factsheet

    Supplement risk analysis